ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
IGM Biosciences Inc

IGM Biosciences Inc (IGMS)

9.49
0.22
( 2.37% )
Updated: 12:06:24

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
9.49
Bid
9.48
Ask
9.52
Volume
22,273
9.2013 Day's Range 9.61
3.81 52 Week Range 17.78
Market Cap
Previous Close
9.27
Open
9.28
Last Trade
1
@
9.51
Last Trade Time
12:07:24
Financial Volume
$ 209,638
VWAP
9.4122
Average Volume (3m)
297,948
Shares Outstanding
58,786,588
Dividend Yield
-
PE Ratio
-2.28
Earnings Per Share (EPS)
-4.19
Revenue
2.13M
Net Profit
-246.42M

About IGM Biosciences Inc

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking ago... IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
1970
IGM Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IGMS. The last closing price for IGM Biosciences was $9.27. Over the last year, IGM Biosciences shares have traded in a share price range of $ 3.81 to $ 17.78.

IGM Biosciences currently has 58,786,588 shares outstanding. The market capitalization of IGM Biosciences is $561.41 million. IGM Biosciences has a price to earnings ratio (PE ratio) of -2.28.

IGMS Latest News

Form S-8 - Securities to be offered to employees in employee benefit plans

  As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Form 8-K - Current report

false000149632300014963232024-03-072024-03-07   UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to...

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...

Form 8-K - Current report

false000149632300014963232024-01-082024-01-08   UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.33-3.360488798379.8210.5758.212966489.10248515CS
4-4.52-32.262669521814.0114.458.2126677310.54864902CS
120.819.331797235028.6817.78.2129794812.13356114CS
261.5419.37106918247.9517.73.813222188.5735568CS
52-6.94-42.239805234316.4317.783.813068119.31806095CS
156-67.96-87.746933505577.4599.443.8132579524.38978345CS
260-8.82-48.170398689218.31127.113.8127127032.46033027CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 21.3184
(348.81%)
19.22M
XLOXilio Therapeutics Inc
$ 1.58
(147.26%)
25.72M
KYCHKeyarch Acquisition Corporation
$ 13.11
(87.14%)
86.05k
BDRXBiodexa Pharmaceuticals PLC
$ 1.46
(69.97%)
75.92M
CEROCERo Therapeutics Holdings Inc
$ 2.485
(52.45%)
6.31M
PMECPrimech Holdings Ltd
$ 1.4505
(-62.62%)
4.3M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
GMDAGamida Cell Ltd
$ 0.0386
(-34.80%)
55.69M
UGROUrban Gro Inc
$ 1.3754
(-24.22%)
392.46k
DTSTData Storage Corporation
$ 5.91
(-22.64%)
591.32k
NKLANikola Corporation
$ 1.01
(11.10%)
112.21M
BDRXBiodexa Pharmaceuticals PLC
$ 1.46
(69.97%)
75.92M
AKANAkanda Corporation
$ 0.1956
(18.62%)
58.78M
GMDAGamida Cell Ltd
$ 0.0386
(-34.80%)
55.69M
MARAMarathon Digital Holdings Inc
$ 23.84
(8.02%)
52.45M

Your Recent History

Delayed Upgrade Clock